pharma news | pharmaphorum

Friday 25 September 2026

pharma news

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

News

Wave's stock wavers on obesity drug data

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

News

AI predicts liver cancer risk with "high accuracy"

AI predicts liver cancer risk with "high accuracy"

A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.

News

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept gets FDA OK for first-in-class ovarian cancer drug

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

News

FDA clears Denali's 'game-changer' Hunter syndrome drug

FDA clears Denali's 'game-changer' Hunter syndrome drug

Denali's Avlayah is the first drug for neurological complications associated Hunter syndrome to be approved in the US.

News

Anavex sinks after pulling Alzheimer's filing in EU

Anavex sinks after pulling Alzheimer's filing in EU

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.